Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition

Characterization of plasma labile heme in hemolytic conditions

(2017) Zélia Gouveia et al.   FEBS Journal

Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study

(2017) Anne S. Strik et al.   GASTROENTEROLOGY

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Molecular and functional analysis of monoclonal antibodies in support of biologics development

(2017) Xin Wang et al.   Protein & Cell

Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors

(2016) Catarina Cunha-Santos et al.   AIDS

Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars

(2016) M Begoña Ruiz-Argüello et al.   ANNALS OF THE RHEUMATIC DISEASES

Assessing the Immunogenicity of Biopharmaceuticals

(2016) Carlos Pineda et al.   BIODRUGS

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

(2016) Joana Afonso et al.   Therapeutic Advances in Gastroenterology

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

(2015) Shomron Ben-Horin et al.   GUT

B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera

(2015) Arne Homann et al.   Journal of Translational Medicine

Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display

(2015) Galber Rodrigues Araujo et al.   ARTHRITIS RESEARCH & THERAPY

Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection

(2015) Klaus Bendtzen   Frontiers in Immunology

A Review of CT-P13: An Infliximab Biosimilar

(2014) Kate McKeage   BIODRUGS

Physicochemical characterization of Remsima®

(2014) Soon Kwan Jung et al.   mAbs

Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact

(2014) Suzanna M Tatarewicz et al.   Bioanalysis

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

(2012) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication

(2012) Frederico Aires da Silva et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

(2009) Melody Sauerborn et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

(2008) Gopi Shankar et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY